Many Drug Companies Creating Abuse-Resistant Painkillers

More than a dozen drug companies are working on abuse-resistant painkillers, in the wake of the Food and Drug Administration’s (FDA) decision last month not to approve any generic versions of the original form of OxyContin.

The FDA also approved new labeling for a reformulated version of the drug, which will indicate it is more difficult to crush, and thus harder to abuse than the original version. The original version of OxyContin could be crushed and then snorted or injected. OxyContin’s manufacturer, Purdue Pharma, introduced a tamper-resistant formula in 2010.

The Wall Street Journal reports the FDA on Friday will consider the effectiveness of another painkiller, Opana ER. If the FDA decides that drug deters abuse, it could help guard Opana’s maker, Endo Pharmaceuticals, from competition, since generic painkillers are not tamper-resistant. That would provide extra incentive to create new painkillers that are resistant to abuse, the article notes. Opana turns into a jellylike substance when it is heated up for injection.

Pfizer has two potential new abuse-resistant drugs: Remoxy, which would compete with OxyContin, and Embeda, a morphine drug. Johnson & Johnson is testing an opioid drug that is tamper-resistant, while Purdue Pharma hopes to produce a hydrocodone drug that is resistant to abuse.

“Over time, it should be a scientific race across the whole pharmaceutical industry to create a market where all opioids have abuse-deterrent properties,” Gary L. Stiles, Senior Vice President of Research and Development at Purdue Pharma, told the newspaper.

Smaller biotech companies are developing their own tamper-resistant formulas. One company has created pills that are so hard, that they chip a coffee grinder’s blades when someone tries to use the device to break down the pills.

    User Picture


    October 9, 2014 at 12:11 PM

    There are a number of bio-pharmas developing abuse resistant painkillers. Elite Pharmaceuticals (ELTP) have a number of patents and is expected to be meeting with the FDA before the end of the year.

    Huge market.

    Physicians are in the crosshairs–with insurance companies, patients and legal enforcement. If they have an alternative to painkillers that are addictive, they will easily move to a new drug. Whoever gets to market first will get the lion share of a major shift in chronic pain management.

    User Picture

    katie hall

    May 7, 2013 at 4:38 PM

    Abuse resistance should be a pre-requisite for FDA approval of a prescription painkillers, not an afterthought.

    User Picture


    May 7, 2013 at 9:54 AM

    And then they will just use heroin. Just like addicts do now when they can no longer afford the higher price of prescription opiates…Simply changing the drug will never work to decrease addiction. The only effective means is to help the addict change.

    User Picture

    Richard Medlin

    May 6, 2013 at 2:10 PM

    I think that “abuse resistance” is a distraction invented by the pharma companies. By the time that “abuse resistance” is an issue, patients are already addicted.

    Unfortunately, the only way to make an opiate containing medication “addiction resistant” is to not prescribe it to patients who will become addicted, which requires a patient selection process that is currently not available.

Leave a Comment

Please leave a comment below to contribute to the discussion. If you have a specific question, please contact a Parent Specialist, who will provide you with one-on-one help.

Your email address will not be published. Required fields are marked *